Provides a definitive, state-of-the-art review of relevant tumor biology and its importance in the broader context of cancer biology

Over the past two decades, a better understanding of the biology of lymphoid malignancies has led to the development of many classes of new, highly active drugs that present opportunities to impact the clinical outcome of many patients.

Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms. This authoritative reference covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).

In-depth chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. Information on monotherapy and combination therapy, summary tables of trials, discussion of toxicity and efficacy, and boxed sections highlighting major points are integrated throughout the text.

Authored and edited by the foremost authorities in the field, Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies is an indispensable resource for medical, scientific, and allied medical professionals.

The Precision Cancer Therapies series helps professionals understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners.

OWEN A. O'CONNOR, MD, PhD, American Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.
 
STEPHEN M. ANSELL, MD, PhD, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
 
JOHN G. GRIBBEN, MD, DSc, Hamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.

List of Contributors xix
 
Volume Foreword xxiv
 
Volume Preface xxvi
 
Series Preface xxviii
 
Section I Historical Perspective 1
 
1 The Distinguished History of Immunotherapy Development in Cancer 3
Stephen M. Ansell
 
Section II Targeting Cell Surface Receptors 9
 
2 Development of Monoclonal Antibodies for the Treatment of Lymphoma: Setting the Stage 11
George J. Weiner
 
3 Pharmacology to Practice: The Similarities and Differences of Drugs Targeting CD20 22
Jennifer K. Lue and Bruce D. Cheson
 
4 Pharmacology to Practice: Targeting CD19 and 22 40
Nilanjan Ghosh and Sonali M. Smith
 
5 Targeting Other Promising Cell Surface Receptors: ROR1, CD38, CD25, and CCR4 52
Michael Wang
 
Section III Antibody Drug Conjugates (ADC) 73
 
6 Principles of Antibody Drug Development 75
Eric L. Sievers
 
7 Targeting CD30 in Lymphoid Neoplasms 87
Barbara Pro
 
8 Targeting CD79b in B-cell Malignancies 100
Colette Owens and Gilles Salles
 
9 Radioimmunotherapy: Is There Any Future Role? 108
Alessandro Broccoli and Pier Luigi Zinzani
 
Section IV Targeting Immune Checkpoint 123
 
10 The Biology of Immune Checkpoint Blockade 125
Timothy N. Bullock
 
11 Mechanism of Action and Pharmacologic Features of Drugs Targeting PD-1/PDL-1 and CTLA-4 139
Marc-Anthony Rodriguez, Ryan Bucktrout, Andrea Orlando, Inna Serganova, and Roberta Zappasodi
 
12 Other Immune Checkpoint Targets of Interest 156
Clifford M. Csizmar and Stephen M. Ansell
 
13 Clinical Experiences with Immune Checkpoint Inhibitors in Lymphomas 190
John M. Timmerman
 
Section V Targeting Macrophages and SIRP-alpha - Disrupting the "Do Not Eat Me" 209
 
14 The Role of CD47 in Lymphoma Biology and Strategies for Therapeutic Targeting 211
Mithunah Krishnamoorthy, Robert A. Uger, and Mark Wong
 
15 Single Agent and Rational Combination Experiences with Anti-CD47 Targeted Drugs 225
Nadia Khan, Swathi Namburi, and Krish Patel
 
Section VI EBV Directed Immunotherapies 233
 
16 Understanding the Role of EBV Infection in Lymphomagenesis 235
Hiroshi Kimura and Takayuki Murata
 
17 Immunologic Therapies in Development for EBV Driven Lymphoid Malignancies 246
Jason Yongsheng CHAN, Seok Jin Kim, Soon Thye LIM, Choon Kiat ONG, and Won Seog Kim
 
Section VII Exploiting Tumor Associated Antigens with Autologous T-Cells 257
 
18 The Scientific Rationale for Targeting Tumor-Associated Antigens 259
Jean-Sébastien Delisle and Marie-France Aubin
 
19 Clinical Experiences with TAA-T in Lymphoid Malignancies 276
Keri Toner, Hannah Kinoshita, and Catherine M. Bollard
 
Section VIII Chimeric Antigen Receptor T-Cells (CAR-T) 289
 
20 The Science of CAR-T Cell Technology 291
Richard C. Godby, Allison M. Bock, Saad S. Kenderian, and Yi Lin
 
21 The Spectrum of CAR T Assets in Development: Similarities and Differences 304
J. Erika Haydu and Jeremy S. Abramson
 
22 Clinical Experience with CAR-T Cells for Treatment of B-cell Lymphomas 318
Stephen J. Schuster and John G. Gribben
 
23 "Off the Shelf" CAR-T/NK Cells 341
Nancy D. Marin, Alice Zhou, Miriam T. Jacobs, and Todd A. Fehniger
 
24 Programming Myeloid Cells with Chimeric Antigen Receptor Myeloid-Based Therapies 360
Miriam Barnett, Michele Gerber, Siddartha Mukherjee, and Daniel Getts
 
Section IX Miscellaneous Topics in Immunotherapy 373
 
25 Mechanistic Basis and Role of Immunomodulatory Drugs 375
John G. Gribben
 
26 Analytical Tools to Quantitate Immune Mediated Effects: What Should We Measure and How? 384
Kevin D. Pavelko and Jose C. Villasboas
 
27 The Role of the Microbiome in Immune Response 397
Máire A. Conrad, Kathleen E. Sullivan, and Judith Kelsen
 
28 Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response 406
Enrica Marchi, Ipsita Pal, John Sanil Manvalan, Kallesh Danappa Jayappa, and Owen A. O'Connor
 
29 Tailoring Specific Radiographic Response Criteria for Immunologic Therapies in Lymphoma 429
Bruce D. Cheson
 
Conclusions 433
 
Must Reads 433
 
References 433
 
Index 436